Abemaciclib plus endocrine therapy significantly improves overall survival in high-risk early breast cancer, reducing death risk by 15.8% compared to endocrine therapy alone.

A microplastics scientist and sustainability expert shares how to avoid microplastics, along with what you should look for in ...

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

Enhertu significantly improved IDFS compared to Kadcyla, with a 53% risk reduction in invasive disease or death in high-risk, ...

T-DXd significantly improved IDFS and reduced the risk of invasive disease or death by 53% compared to T-DM1 in high-risk, HER2-positive breast cancer patients. The trial demonstrated superior ...

In September 2024, Sanofi entered an exclusive licensing agreement with Orano Med and RadioMedix to globally commercialize ...

Chronic inflammation is the invisible drain on American vitality, but it is not an inevitable part of aging. The most ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk ...

If you've spent some time around a member of Generation Alpha lately, you've likely heard them use some pretty ...

Collective Mining Ltd. (NYSE: CNL) (TSX: CNL) ("Collective" or the "Company") is pleased to provide an exploration update and ...

Amex Exploration Inc. (TSXV: AMX) (FSE: MX0) (OTCQX: AMXEF) ("Amex" or the "Company") is pleased to announce that the ...